MENU
+Compare
BFRI
Stock ticker: NASDAQ
AS OF
Apr 17 closing price
Price
$0.85
Change
+$0.02 (+2.41%)
Capitalization
9.77M

BFRI Biofrontera Forecast, Technical & Fundamental Analysis

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy... Show more

BFRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for BFRI with price predictions
Apr 17, 2025

BFRI's Stochastic Oscillator is remaining in overbought zone for 4 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BFRI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BFRI entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BFRI's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 11, 2025. You may want to consider a long position or call options on BFRI as a result. In of 55 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BFRI just turned positive on April 11, 2025. Looking at past instances where BFRI's MACD turned positive, the stock continued to rise in of 27 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BFRI advanced for three days, in of 152 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.039) is normal, around the industry mean (60.843). P/E Ratio (0.000) is within average values for comparable stocks, (89.540). BFRI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (0.087) is also within normal values, averaging (20.019).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BFRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
BFRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

BFRI is expected to report earnings to fall 21.43% to -21 cents per share on August 11

Biofrontera BFRI Stock Earnings Reports
Q2'23
Est.
$-0.22
Q1'23
Missed
by $0.20
Q4'22
Missed
by $0.04
Q3'22
Beat
by $0.18
Q2'22
Beat
by $0.29
The last earnings report on May 12 showed earnings per share of -28 cents, missing the estimate of -7 cents. With 18.96K shares outstanding, the current market capitalization sits at 9.77M.
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
120 Presidential Way
Phone
+1 781 245-1325
Employees
85
Web
https://www.biofrontera-us.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
BTC.X85063.414000612.609400
+0.73%
Bitcoin cryptocurrency
SPY525.66N/A
N/A
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla

BFRI and Stocks

Correlation & Price change

A.I.dvisor tells us that BFRI and CRON have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BFRI and CRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BFRI
1D Price
Change %
BFRI100%
+1.80%
CRON - BFRI
21%
Poorly correlated
N/A
COLL - BFRI
21%
Poorly correlated
-0.04%
PLSH - BFRI
17%
Poorly correlated
N/A
SHPH - BFRI
16%
Poorly correlated
-0.98%
CRDL - BFRI
15%
Poorly correlated
N/A
More